Format

Send to

Choose Destination
J Epidemiol. 2017 Mar;27(3S):S2-S8. doi: 10.1016/j.je.2016.12.005. Epub 2017 Feb 8.

Overview of the BioBank Japan Project: Study design and profile.

Author information

1
Department of Public Policy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
2
Laboratory of Genome Technology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
3
Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
4
Laboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Laboratory of Clinical Genome Sequencing, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
5
Hisayama Research Institute for Lifestyle Diseases, Fukuoka, Japan.
6
Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
7
Department of Public Health, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
8
Department of Health Sciences, University of Yamanashi, Yamanashi, Japan.
9
Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
10
Division of Molecular Pathology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
11
Project Division of International Advanced Medical Research, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
12
Division of Clinical Genome Research, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
13
Laboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Division of Genetics, National Cancer Center Research Institute, Tokyo, Japan.
14
SNP Research Center, RIKEN Yokohama Institute, Yokohama, Japan; Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan; Bioresource Research Center, Tokyo Medical and Dental University, Tokyo, Japan.
15
SNP Research Center, RIKEN Yokohama Institute, Yokohama, Japan; Shinko Clinic, Medical Corporation Shinkokai, Tokyo, Japan.
16
Laboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, USA.
17
RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. Electronic address: michiaki.kubo@riken.jp.
18
Tokushukai Hospitals, Japan.
19
Nippon Medical School, Japan.
20
Juntendo University, Japan.
21
Nihon University, Japan.
22
Iwate Medical University, Japan.
23
Tokyo Metropolitan Institute of Gerontology, Japan.
24
The Cancer Institute Hospital of JFCR, Japan.
25
Aso Iizuka Hospital, Japan.
26
Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan.
27
Shiga University of Medical Science, Japan.
28
National Hospital Organization, Osaka National Hospital, Japan.
29
Fukujuji Hospital, Japan.

Abstract

BACKGROUND:

The BioBank Japan (BBJ) Project was launched in 2003 with the aim of providing evidence for the implementation of personalized medicine by constructing a large, patient-based biobank (BBJ). This report describes the study design and profile of BBJ participants who were registered during the first 5-year period of the project.

METHODS:

The BBJ is a registry of patients diagnosed with any of 47 target common diseases. Patients were enrolled at 12 cooperative medical institutes all over Japan from June 2003 to March 2008. Clinical information was collected annually via interviews and medical record reviews until 2013. We collected DNA from all participants at baseline and collected annual serum samples until 2013. In addition, we followed patients who reported a history of 32 of the 47 target diseases to collect survival data, including cause of death.

RESULTS:

During the 5-year period, 200,000 participants were registered in the study. The total number of cases was 291,274 at baseline. Baseline data for 199,982 participants (53.1% male) were available for analysis. The average age at entry was 62.7 years for men and 61.5 years for women. Follow-up surveys were performed for participants with any of 32 diseases, and survival time data for 141,612 participants were available for analysis.

CONCLUSIONS:

The BBJ Project has constructed the infrastructure for genomic research for various common diseases. This clinical information, coupled with genomic data, will provide important clues for the implementation of personalized medicine.

KEYWORDS:

BioBank Japan Project; Biobank; Genomic research; Personalized medicine

PMID:
28189464
PMCID:
PMC5350590
DOI:
10.1016/j.je.2016.12.005
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center